BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer

Phase II Randomized Trial of the Polo-like Kinase 1 Inhibitor BI 6727 Monotherapy Versus Investigator´s Choice Chemotherapy in Ovarian Cancer Patients Resistant or Refractory to Platinum-based Cytotoxic Therapy

This is an international, randomized phase II trial. The aim is to assess the efficacy and the safety of BI 6727 Versus investigator's best choice single agent cytotoxic in recurrent third and fourth lines platinum resistant/refractory ovarian cancer.

100 patients will be randomised at the study entry to receive either BI 6727 (Arm A: 50 patients) or non-platinum single agent cytotoxic (Arm B: 50 patients) Treatment will be continued until disease progression or unacceptable toxicity. Primary endpoint: disease control rate at week 24 according to Response Evaluation Criteria In Solid Tumours version 1.1.

Secondary endpoints: efficacy (progression free survival, overall survival, biological tumour response, biological progression free survival assessed by serum CA 125 according to Gynecologic Cancer Intergroup criteria, safety according to the NCI CTCAE v.3, disease symptoms control assessed by the EORTC QLQ-C30, QLQ-OV28 and individual symptoms questionnaires, pharmacokinetics of BI 6727.

Others endpoints: biomarkers and pharmacogenetics analysis (optional)

Study Overview

• Status: Completed
• Conditions: Ovarian Neoplasms
• Intervention / Treatment: Drug: BI 6727; Drug: Paclitaxel; Drug: Gemcitabine; Drug: Topotecan; Drug: Pegylated liposomal doxorubicin (PLD)

• Study Type: Interventional
• Enrollment (Actual): 110
• Phase: Phase 2

Contacts and Locations

Study Locations

• Belgium
  • Brussel, Belgium
    • 1230.18.32003 Boehringer Ingelheim Investigational Site
  • Edegem, Belgium
    • 1230.18.32004 Boehringer Ingelheim Investigational Site
  • Gent, Belgium
    • 1230.18.32002 Boehringer Ingelheim Investigational Site
  • Leuven, Belgium
    • 1230.18.32001 Boehringer Ingelheim Investigational Site
• France
  • Angers Cedex 9, France
    • 1230.18.3321A Boehringer Ingelheim Investigational Site
  • Bordeaux cedex, France
    • 1230.18.3307A Boehringer Ingelheim Investigational Site
  • Caen, France
    • 1230.18.3301A Boehringer Ingelheim Investigational Site
  • Lille Cedex, France
    • 1230.18.3322A Boehringer Ingelheim Investigational Site
  • Lyon, France
    • 1230.18.3313A Boehringer Ingelheim Investigational Site
  • Nantes cedex 02, France
    • 1230.18.3312A Boehringer Ingelheim Investigational Site
  • Nice cedex, France
    • 1230.18.3308A Boehringer Ingelheim Investigational Site
  • Paris, France
    • 1230.18.3302A Boehringer Ingelheim Investigational Site
  • Paris Cedex 20, France
    • 1230.18.3314A Boehringer Ingelheim Investigational Site
  • Pierre-Bénite cedex, France
    • 1230.18.3309A Boehringer Ingelheim Investigational Site
  • Reims cedex, France
    • 1230.18.3305A Boehringer Ingelheim Investigational Site
  • Saint-Brieuc cedex, France
    • 1230.18.3320A Boehringer Ingelheim Investigational Site
  • Strasbourg, France
    • 1230.18.3311A Boehringer Ingelheim Investigational Site
  • Toulouse Cedex 9, France
    • 1230.18.3310A Boehringer Ingelheim Investigational Site
  • Vandoeuvre les Nancy cedex, France
    • 1230.18.3315A Boehringer Ingelheim Investigational Site
• Slovakia
  • Bratislava, Slovakia
    • 1230.18.42101 Boehringer Ingelheim Investigational Site
  • Poprad, Slovakia
    • 1230.18.42103 Boehringer Ingelheim Investigational Site
• Spain
  • Badalona, Spain
    • 1230.18.34006 Boehringer Ingelheim Investigational Site
  • Barcelona, Spain
    • 1230.18.34001 Boehringer Ingelheim Investigational Site
  • Barcelona, Spain
    • 1230.18.34005 Boehringer Ingelheim Investigational Site
  • Girona, Spain
    • 1230.18.34007 Boehringer Ingelheim Investigational Site
  • L'Hospitalet de Llobregat, Spain
    • 1230.18.34004 Boehringer Ingelheim Investigational Site
  • Madrid, Spain
    • 1230.18.34002 Boehringer Ingelheim Investigational Site
  • Madrid, Spain
    • 1230.18.34003 Boehringer Ingelheim Investigational Site
• Sweden
  • Linköping, Sweden
    • 1230.18.46005 Boehringer Ingelheim Investigational Site
  • Stockholm, Sweden
    • 1230.18.46001 Boehringer Ingelheim Investigational Site
  • Uppsala, Sweden
    • 1230.18.46003 Boehringer Ingelheim Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion criteria:

1. Confirmed recurrent epithelial ovarian carcinoma, peritoneal carcinoma or fallopian tube carcinoma.
2. Platinum resistant or platinum refractory disease.
3. Eastern Collaborative Oncology Group performance status < = 2.
4. Life expectancy > = 3 months.
5. At least one measurable lesion (Response Evaluation Criteria In Solid Tumours version 1.1).
6. Adequate hepatic, renal and bone marrow functions.
7. signed written informed consent prior to admission to the study.

Exclusion criteria:

1. Contre-indications for cytotoxic treatment according to the Summary of Product Characteristics (Arm B).
2. Clinical evidence of active brain metastasis or leptomeningeal involvement.
3. Other malignancy currently requiring active therapy.
4. QTc prolongation according to Fridericia formula deemed clinically relevant by the investigator (e.g., congenital long QT syndrome, QTc according to Fridericia formula > 470 ms).
5. Hypersensitivity to one of the trial drugs or the excipients.
6. Serious illness or concomitant non- oncological disease.
7. Systemic anticancer therapy within 4 weeks before the start of the study.
8. Evidence of ileus sor sub ileus.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: BI 6727; Patients receive BI 6727 infusion every 3 weeks	Drug: BI 6727; Patients receive BI 6727 infusion every 3 weeks
Active Comparator: Cytotoxic; At the investigator discretion, patient will receive one of the following cytotoxics: topotecan, paclitaxel, gemcitabine or liposomal doxorubicin	Drug: Paclitaxel; Patients receive paclitaxel in a 4 week schedule; Drug: Gemcitabine; Patients receive gemcitabine in a 3 week schedule; Drug: Topotecan; Patients receive topotecan in 3 or 4 week schedule; Drug: Pegylated liposomal doxorubicin (PLD); Patients receive PLD in a 4 week schedule

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Disease Control Rate (DCR) at Week 24 According to Response Evaluation Criteria In Solid Tumours (RECIST) Version 1.1	DCR was defined as the proportion of patients who had an overall response of complete response (CR), partial response (PR), or stable disease (SD).	Week 24

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression Free Survival (PFS)	Progression-free survival of a patient was based on the investigator's assessment; it was defined as the number of days from the date of randomisation until the date of either disease progression or death from any cause, whichever occurred first. Definition of disease progression according to RECIST version 1.1; Patients with measurable tumour lesions at baseline, Target-lesions: at least a 20% increase in the sum of diameters of target lesions, the sum of diameters must also demonstrate an absolute increase of at least 5 mm,taking as reference the smallest sum on study, or appearance of 1 or more new lesions. Non-target lesions: unequivocal progression of existing non-target lesions or appearance of 1 or more new lesions Patients with non-measurable tumour lesions at baseline, Non-target lesions: requires unequivocal progression of existing non-target lesions or appearance of 1 or more new lesions	From randomization until disease progression, death or study discontinuation; Up to 213 weeks
Overall Survival (OS)	OS is defined as time from randomisation to death irrespective of the cause of the death.	From randomization until death or study discontinuation; Up to 213 weeks
Best Overall Response	Best overall response (BOR) is defined as the best response recorded at any time from the date of randomisation until the end of treatment. Missing categories signify that no tumour imaging has been performed post baseline, and therefore the response status could not be assessed.	time from the date of randomisation until study completion/discontinuation; Up to 213 weeks
Biological Tumour Response Based on Serum Cancer Antigen 125 (CA-125) According to the Gynaecologic Cancer Intergroup (GCIG) Criteria	Patients were to have a pre-treatment CA-125 of at least twice the upper limit of normal to be considered for CA-125 response. Patients were not evaluable by CA-125 if they had received mouse antibodies or if they had undergone medical and/or surgical interference with their peritoneum or pleura during the previous 28 days. In eligible patients, a CA-125 response was defined as the moment the CA- 25 was reduced by 50%, with this being confirmed with a consecutive CA-125 assessment not earlier than 28 days after the previous one. Biological response rate based on serum CA-125 levels was assessed according to the guidelines by the Gynaecologic Cancer Intergroup. Monitoring of blood levels of the tumour marker CA-125 was performed at screening and every 6 weeks thereafter.	At screening and every 6 weeks thereafter (Up to 213 weeks)
Biological Progression-free Survival Based on Serum Cancer Antigen 125 (CA-125) According to the Gynaecologic Cancer Intergroup (GCIG) Criteria	Biological PFS including assessment of CA-125 levels was defined as the time from randomisation until the first occurrence of progressive disease according to CA-125, progressive disease according to radiological evidence, or death. Also according to the below criterias,; In patients with radiological measurable disease, disease progression during study treatment could not be declared on the basis of CA-125 alone.; Patients with elevated CA-125 pre-treatment and normalization of CA-125 had to show evidence of CA-125 ≥ to two times the upper normal limit on two occasions at least one week apart or; Patients with elevated CA-125 pre-treatment, which never normalized, had to show evidence of CA-125 ≥ to two times the nadir value on two occasions at least one week apart or; Patients with CA-125 in the normal range pre-treatment had to show evidence of CA-125 ≥ to two times the upper normal limit on two occasions at least one week apart.	At screening and every 6 weeks thereafter (Up to 213 weeks )
Time to Deterioration in Global Health Status/Quality of Life (QOL)	Time to deterioration in global health status/Quality of life (QOL) and symptom control assessed by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, QLQ-OV28, and individual symptom questionnaires. The time to deterioration was defined as the time from randomisation to a score increased (i.e. worsened) by at least 10 points from baseline (0-100 point scale). If score is missing, and patient died within 28 days after scheduled time for completion, the patient was considered deteriorated. In this case, time to deterioration is time to death.	Every 6 weeks (Up to 213 weeks )
Time to Deterioration in Fatigue/Quality of Life (QOL)	Time to deterioration in fatigue/Quality of life (QOL) and symptom control assessed by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, QLQ-OV28, and individual symptom questionnaires. The time to deterioration was defined as the time from randomisation to a score increased (i.e. worsened) by at least 10 points from baseline (0-100 point scale). If score is missing, and patient died within 28 days after scheduled time for completion, the patient was considered deteriorated. In this case, time to deterioration is time to death.	Every 6 weeks (Up to 213 weeks )
Time to Deterioration in Pain/ Quality of Life (QOL)	Time to deterioration in pain/ Quality of life (QOL) and symptom control assessed by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, QLQ-OV28, and individual symptom questionnaires. The time to deterioration was defined as the time from randomisation to a score increased (i.e. worsened) by at least 10 points from baseline (0-100 point scale). If score is missing, and patient died within 28 days after scheduled time for completion, the patient was considered deteriorated. In this case, time to deterioration is time to death.	Every 6 weeks (Up to 213 weeks )
Time to Deterioration in Abdominal Bloating/ Quality of Life (QOL)	Time to deterioration in abdominal bloating/ Quality of life (QOL) and symptom control assessed by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, QLQ-OV28, and individual symptom questionnaires. The time to deterioration was defined as the time from randomisation to a score increased (i.e. worsened) by at least 10 points from baseline (0-100 point scale). If score is missing, and patient died within 28 days after scheduled time for completion, the patient was considered deteriorated. In this case, time to deterioration is time to death.	Every 6 weeks (Up to 213 weeks )
Time to Deterioration in the Three Most Troublesome Disease Specific Symptoms/ Quality of Life (QOL)	Three most troublesome disease specific symptoms, defined by the patient at baseline. Patients that have defined more than 3 most troublesome symptoms have not been taken into account in the analysis. Quality of life (QOL) and symptom control assessed by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, QLQ-OV28, and individual symptom questionnaires. The time to deterioration was defined as the time from randomisation to a score increased (i.e. worsened) by at least 10 points from baseline (0-100 point scale). If score is missing, and patient died within 28 days after scheduled time for completion, the patient was considered deteriorated. In this case, time to deterioration is time to death.	Every 6 weeks (Up to 213 weeks)
Incidence and Intensity of Adverse Events According to the United States National Cancer Institute (US NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0	Incidence and intensity of adverse events according to the United States National Cancer Institute (US NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0	From first treatment administration to 21 days after the last drug administration (Up to 1403 days)
Clinically Relevant Changes in Laboratory and ECG Data	Clinically relevant changes in laboratory and ECG data	From first treatment administration to 21 days after the last drug administration (Up to 1403 days)
AUC (0-24); Area Under the Concentration-time Curve in Plasma Over the Time Interval From 0 to 24 Hours for BI 6727 BS	AUC (0-24); area under the concentration-time curve in plasma over the time interval from 0 to 24 hours for BI 6727 BS	-0.083 hours (h), 2h, 4h, 6h, 24h, 168h and 336 h after first drug administration
AUC (0-24); Area Under the Concentration-time Curve in Plasma Over the Time Interval From 0 to 24 Hours for CD 10899 BS	AUC (0-24); area under the concentration-time curve in plasma over the time interval from 0 to 24 hours for CD 10899 BS (metabolite of Volasertib BI 6727)	-0.083 hours (h), 2h, 4h, 6h, 24h, 168h and 336 h after first drug administration
AUC (0-inf); Area Under the Concentration-time Curve in Plasma Over the Time Interval From 0 Extrapolated to Infinity for BI 6727 BS	AUC (0-inf); area under the concentration-time curve in plasma over the time interval from 0 extrapolated to infinity for BI 6727 BS	-0.083 hours (h), 2h, 4h, 6h, 24h, 168h and 336 h after first drug administration
AUC (0-inf); Area Under the Concentration-time Curve in Plasma Over the Time Interval From 0 Extrapolated to Infinity for CD 10899 BS	AUC (0-inf); area under the concentration-time curve in plasma over the time interval from 0 extrapolated to infinity for CD 10899 BS (metabolite of Volasertib BI 6727)	-0.083 hours (h), 2h, 4h, 6h, 24h, 168h and 336 h after first drug administration
Cmax; Maximum Measured Concentration of BI 6727 BS in Plasma	Cmax; maximum measured concentration of BI 6727 BS in plasma	-0.083 hours (h), 2h, 4h, 6h, 24h, 168h and 336 h after first drug administration
Cmax; Maximum Measured Concentration of CD 10899 BS in Plasma	Cmax; maximum measured concentration of CD 10899 BS (metabolite of Volasertib BI 6727) in plasma	-0.083 hours (h), 2h, 4h, 6h, 24h, 168h and 336 h after first drug administration
Tmax; Time From Dosing to Maximum Measured Concentration of BI 6727 BS in Plasma	tmax; time from dosing to maximum measured concentration of BI 6727 BS in plasma	-0.083 hours (h), 2h, 4h, 6h, 24h, 168h and 336 h after first drug administration
Tmax; Time From Dosing to Maximum Measured Concentration of CD 10899 BS in Plasma	tmax; time from dosing to maximum measured concentration of CD 10899 BS (metabolite of Volasertib BI 6727) in plasma	-0.083 hours (h), 2h, 4h, 6h, 24h, 168h and 336 h after first drug administration
t1/2; Terminal Half-life of BI 6727 BS in Plasma	t1/2; Terminal half-life of BI 6727 BS in plasma	-0.083 hours (h), 2h, 4h, 6h, 24h, 168h and 336 h after first drug administration
t1/2; Terminal Half-life of CD 10899 BS in Plasma	t1/2; Terminal half-life of CD 10899 BS in plasma	-0.083 hours (h), 2h, 4h, 6h, 24h, 168h and 336 h after first drug administration
MRT; Mean Residence Time of BI 6727 BS in the Body	MRT; Mean residence time of BI 6727 BS in the body	-0.083 hours (h), 2h, 4h, 6h, 24h, 168h and 336 h after first drug administration
CL; Total Clearance of BI 6727 BS in Plasma After Intravenous Administration	CL; total clearance of BI 6727 BS in plasma after intravenous administration	-0.083 hours (h), 2h, 4h, 6h, 24h, 168h and 336 h after first drug administration
Vss;Apparent Volume of Distribution at Steady State Following Intravenous Administration for BI 6727 BS	Vss;apparent volume of distribution at steady state following intravenous administration for BI 6727 BS	-0.083 hours (h), 2h, 4h, 6h, 24h, 168h and 336 h after first drug administration
Biomarkers and Pharmacogenetics Analysis (Optional)	This endpoint has not been statistically analysed in the study report	6 months

Collaborators and Investigators

• Sponsor: Boehringer Ingelheim

Publications and helpful links

General Publications

• Pujade-Lauraine E, Selle F, Weber B, Ray-Coquard IL, Vergote I, Sufliarsky J, Del Campo JM, Lortholary A, Lesoin A, Follana P, Freyer G, Pardo B, Vidal L, Tholander B, Gladieff L, Sassi M, Garin-Chesa P, Nazabadioko S, Marzin K, Pilz K, Joly F. Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study. J Clin Oncol. 2016 Mar 1;34(7):706-13. doi: 10.1200/JCO.2015.62.1474. Epub 2016 Jan 11.

Helpful Links

• Related Info

Study record dates

Study Major Dates

• Study Start: April 1, 2010
• Primary Completion (Actual): June 1, 2014
• Study Completion (Actual): June 1, 2014

Study Registration Dates

• First Submitted: April 13, 2010
• First Submitted That Met QC Criteria: May 10, 2010
• First Posted (Estimate): May 12, 2010

Study Record Updates

• Last Update Posted (Estimate): August 13, 2015
• Last Update Submitted That Met QC Criteria: July 17, 2015
• Last Verified: July 1, 2015

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Genital Neoplasms, Female; Endocrine System Diseases; Ovarian Diseases; Adnexal Diseases; Gonadal Disorders; Endocrine Gland Neoplasms; Ovarian Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Enzyme Inhibitors; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Antineoplastic Agents, Phytogenic; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Antibiotics, Antineoplastic; Topoisomerase I Inhibitors; Gemcitabine; Paclitaxel; Doxorubicin; Liposomal doxorubicin; Topotecan
• Other Study ID Numbers: 1230.18; 2009-015770-35 (EudraCT Number: EudraCT)